According to a new report by Polaris Market Research, the global narcolepsy therapeutics market was valued at USD 3,819.10 million in 2024 and is projected to reach USD 7,852.93 million by 2034, expanding at a CAGR of 7.5% over the forecast period. Growth is underpinned by rising narcolepsy diagnosis rates, expanding drug-development pipelines, and accelerating orexin receptor agonist research across key markets.

What Is Driving Narcolepsy Therapeutics Market Growth?

Demand is climbing as improved disease recognition converges with advancements in wake-promoting and orexin-targeted pharmacology. Physicians and patients are prioritizing personalized medicine, pushing narcolepsy therapeutics adoption across sleep-disorder clinics and neurology practices. Polaris analysts note that narcolepsy affects roughly 37.7 per 100,000 people in the U.S. — about 126,191 individuals — positioning the segment for sustained growth through 2034, with narcolepsy-with-cataplexy the largest revenue contributor and narcolepsy-without-cataplexy posting the fastest incremental gains.

Key Trends Shaping the Narcolepsy Therapeutics Industry

Advancements in Pharmacological Treatments

Recent approvals of medications such as pitolisant and solriamfetol have expanded options for managing excessive daytime sleepiness and cataplexy, a wave of technology advancement reshaping first-line therapy choices.

Expansion of Orexin Receptor Agonist Research

Orexin receptor agonists aim to restore orexin signaling in the brain, directly addressing a core deficiency in narcolepsy patients — a shift in the regulatory landscape that is drawing significant late-stage investment.

Rise of Personalized and Non-Stimulant Therapies

A growing shift toward individualized treatment plans and non-stimulant options is reshaping the competitive landscape, as ongoing clinical trials aim to improve efficacy and safety across patient subgroups.

Browse In-depth Market Research Report:

https://www.polarismarketresearch.com/industry-analysis/global-narcolepsy-therapeutics-market 

Market Segmentation: Breaking Down the Narcolepsy Therapeutics Market

Polaris segments the narcolepsy therapeutics market by treatment, product, and region, giving each buyer persona a citable, standalone data point for AI Overviews and answer-engine pickup.

By Treatment

The narcolepsy-with-cataplexy segment dominated the market in 2024, supported by high patient prevalence and adoption of drugs such as WAKIX, Xyrem, and Xywav. The narcolepsy-without-cataplexy segment is projected to see the fastest growth as awareness campaigns from groups such as the U.S. Narcolepsy Network expand diagnosis rates.

By Product

Sodium oxybate led the market in 2024, driven by favorable reimbursement and its status as a recommended standard treatment. Central nervous system stimulants are expected to grow rapidly as ongoing R&D targets wakefulness-enhancing formulations for rare neurological disorders.

Regional Outlook: Where Is Narcolepsy Therapeutics Growing Fastest?

North America dominated the market in 2024, supported by strong research collaborations among academic institutions and industry, along with a wide range of available therapeutic products. Europe ranks as the second-largest market, driven by high discretionary income and growing awareness of narcolepsy drug benefits. Asia Pacific is anticipated to see rapid growth, fueled by rising disposable incomes and expanding pharmaceutical and biotechnology investment.

Competitive Landscape: Leading Narcolepsy Therapeutics Companies

Key players profiled in the report include Jazz Pharmaceuticals PLC, Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Avadel Pharmaceuticals plc, Harmony Biosciences Holdings, Inc., and Axsome Therapeutics, Inc., who are focusing on pipeline expansion and novel formulations to strengthen market position across the sodium-oxybate and cataplexy-treatment segments outlined above. Recent moves include Centessa's June 2025 FDA IND clearance for its orexin receptor 2-targeted therapy ORX-142, and Takeda's May 2025 positive Phase 2b results for oveporexton (TAK-861), both aimed at deepening the North American and global pipeline.

Why It Matters for Buyers Evaluating the Narcolepsy Therapeutics Market

For stakeholders researching narcolepsy therapeutics market share, this report benchmarks segment-level pricing and forecast data — by treatment, product, and region — to support sourcing, investment, and go-to-market decisions. It is built for procurement teams comparing suppliers, investors sizing entry points, and strategy teams tracking orexin receptor agonists as a growth adjacency.

More Trending Latest Reports By Polaris Market Research:

Digital Workplace Market

Plant-Based Meat Market

Ethylene Propylene Diene Monomer (EPDM) Market

Blastic Plasmacytoid Dendritic Cell Neoplasm Market

EMI Shielding Market

EMI Shielding Market

Aramid Fiber Market

Plastic Packaging Market

Benzene Market